MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- STRIDES PHARMA SCIENCE - ACTAVIS (US)
STRIDES PHARMA SCIENCE vs ACTAVIS (US) - Comparison Results
ACTAVIS (US)
Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
Financials
 STRIDES PHARMA SCIENCE  ACTAVIS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| STRIDES PHARMA SCIENCE Mar-21 |
ACTAVIS Dec-18 |
STRIDES PHARMA SCIENCE/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,000 | 15,288 | - | |
| Low | Rs | 304 | 10,255 | - | |
| Sales per share (Unadj.) | Rs | 369.7 | 3,750.2 | - | |
| Earnings per share (Unadj.) | Rs | 39.6 | -1,208.0 | - | |
| Cash flow per share (Unadj.) | Rs | 62.6 | 395.2 | - | |
| Dividends per share (Unadj.) | Rs | 2.50 | 0 | - | |
| Avg Dividend yield | % | 0.4 | 0 | - | |
| Book value per share (Unadj.) | Rs | 309.1 | 15,468.0 | - | |
| Shares outstanding (eoy) | m | 89.68 | 332.60 | - | |
| Bonus / Rights / Conversions | 0 | 0 | - | ||
| Price / Sales ratio | x | 1.8 | 3.4 | 51.8% | |
| Avg P/E ratio | x | 16.4 | -10.6 | -155.5% | |
| P/CF ratio (eoy) | x | 10.4 | 32.3 | 32.2% | |
| Price / Book Value ratio | x | 2.1 | 0.8 | 255.4% | |
| Dividend payout | % | 6.3 | 0 | - | |
| Avg Mkt Cap | Rs m | 58,465 | 4,247,956 | 1.4% | |
| No. of employees | `000 | NA | 16.9 | 0.0% | |
| Total wages/salary | Rs m | 5,501 | 0 | - | |
| Avg. sales/employee | Rs Th | 0 | 73,806.6 | - | |
| Avg. wages/employee | Rs Th | 0 | 0 | - | |
| Avg. net profit/employee | Rs Th | 0 | -23,773.1 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 33,159 | 1,247,331 | 2.7% | |
| Other income | Rs m | 734 | 23,853 | 3.1% | |
| Total revenues | Rs m | 33,893 | 1,271,184 | 2.7% | |
| Gross profit | Rs m | 6,702 | 32,686 | 20.5% | |
| Depreciation | Rs m | 2,063 | 533,207 | 0.4% | |
| Interest | Rs m | 1,501 | 71,978 | 2.1% | |
| Profit before tax | Rs m | 3,872 | -548,645 | -0.7% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 139,927 | 0.0% | |
| Tax | Rs m | 317 | -6,953 | -4.6% | |
| Profit after tax | Rs m | 3,555 | -401,766 | -0.9% | |
| Gross profit margin | % | 20.2 | 2.6 | 771.3% | |
| Effective tax rate | % | 8.2 | 1.3 | 645.0% | |
| Net profit margin | % | 10.7 | -32.2 | -33.3% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 28,172 | 511,590 | 5.5% | |
| Current liabilities | Rs m | 27,383 | 452,569 | 6.1% | |
| Net working cap to sales | % | 2.4 | 4.7 | 50.3% | |
| Current ratio | x | 1.0 | 1.1 | 91.0% | |
| Inventory Days | Days | 165 | 20 | 843.4% | |
| Debtors Days | Days | 122 | 66 | 183.7% | |
| Net fixed assets | Rs m | 39,996 | 141,191 | 28.3% | |
| Share capital | Rs m | 897 | 0 | - | |
| Net worth | Rs m | 27,719 | 5,144,657 | 0.5% | |
| Long term debt | Rs m | 8,826 | 1,811,620 | 0.5% | |
| Total assets | Rs m | 68,168 | 8,042,270 | 0.8% | |
| Interest coverage | x | 3.6 | -6.6 | -54.1% | |
| Debt to equity ratio | x | 0.3 | 0.4 | 90.4% | |
| Sales to assets ratio | x | 0.5 | 0.2 | 313.6% | |
| Return on assets | % | 7.4 | -4.1 | -180.9% | |
| Return on equity | % | 12.8 | -7.8 | -164.2% | |
| Return on capital | % | 14.7 | -4.8 | -303.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 4,814 | 445,624 | 1.1% | |
| From Investments | Rs m | -5,208 | 244,812 | -2.1% | |
| From Financial Activity | Rs m | -158 | -764,825 | 0.0% | |
| Net Cashflow | Rs m | -564 | -74,017 | 0.8% | |
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 79.01 Rs / USD
Compare STRIDES PHARMA SCIENCE With: MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare STRIDES PHARMA SCIENCE With: GRANULES INDIA CIAN HEALTHCARE ASTRAZENECA PHARMA PROCTER & GAMBLE HEALTH ABBOTT INDIA
Today's Market
Sensex Ends 150 Points Lower, Nifty Falls Below 15,800; FMCG & Banking Stocks Witness Selling(Closing)
After opening deep in the red, Indian share markets recovered most of the losses as the session progressed but still ended on a negative note.
Related Views On News
The Most Oversold Stocks in India. Is it Finally Time to Get in? (Views On News)
Jan 7, 2022With the help of relative strength index (RSI), we take a look at top stocks that are oversold at current levels.
5 Takeaways from Sun Pharma's Q4 Results (Views On News)
May 30, 2022It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.
Why Divi's Lab Share Price is Falling (Views On News)
May 24, 2022Here's why Divi's Lab's stock fell over 10% in two days.
Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)
May 23, 2022For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)
May 19, 2022During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
More Views on NewsMost Popular
4 Sectors to Watch for Future Multibagger Stocks (Views On News)
Jun 17, 2022With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.
Best Monopoly Stocks to Own in 2022 
(Views On News)
Jun 18, 2022
Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.
Is it Time to Start Buying Stocks Selectively? (Profit Hunter)
Jun 16, 2022Some sectors have corrected by 50%. Do they merit a look?
The One Smallcap Stock I'll Recommend Now (Profit Hunter)
Jun 21, 2022This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.
When Will the Stock Market Recover? (Views On News)
Jun 15, 2022This is how you can tell the market is going to recover.
MoreOUR TOP 5 IDEAS
STRIDES PHARMA SCIENCE SHARE PRICE
Jun 29, 2022 03:32 PM
TRACK STRIDES PHARMA SCIENCE
- Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON STRIDES PHARMA SCIENCE
STRIDES PHARMA SCIENCE 8-QTR ANALYSIS
COMPARE STRIDES PHARMA SCIENCE WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks in 2022
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.